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Background: Determination of vancomycin minimum inhibitory concentration (MIC) can 
influence the agent used to treat methicillin-resistant Staphylococcus aureus (MRSA) infec-
tion. We studied diagnostic accuracy using E-test and VITEK® 2 against a gold standard broth 
microdilution (BMD) methodology, the correlation between methods, and associations between 
vancomycin MIC and MRSA phenotype from clinical isolates.
Methods: MRSA isolates were obtained from April 2012 to December 2013. Vancomycin MIC 
values were determined prospectively on all isolates by gradient diffusion E-test and automated 
VITEK® 2. The Clinical and Laboratory Standards Institute reference BMD method was performed 
retrospectively on thawed frozen isolates. Diagnostic accuracy for detecting less susceptible strains 
was calculated at each MIC cutoff point for E-Test and VITEK® 2 using BMD ≥1 µg/mL as a 
standard. The correlation between methods was assessed using Spearman’s rho (r). The association 
between MRSA phenotype and MIC for the three methods was assessed using Fisher’s exact test.
Results: Of 148 MRSA isolates, all except one (E-test =3 µg/mL) were susceptible to van-
comycin (MIC of ≤2 µg/mL) irrespective of methodology. MICs were ≥1.0 µg/mL for 9.5% 
of BMD, 50.0% for VITEK® 2, and 27.7% for E-test. Spearman’s r showed weak correlations 
between methods: 0.29 E-test vs VITEK® 2 (P=0.003), 0.27 E-test vs BMD (P=0.001), and 
0.31 VITEK® 2 vs BMD (P=0.002). The optimal cutoff points for detecting BMD-defined less 
susceptible strains were ≥1.0 µg/mL for E-test and VITEK® 2. E-test sensitivity at this cutoff 
point was 0.85 and specificity 0.29, while VITEK® 2 sensitivity and specificity were 0.62 and 
0.51, respectively. Multiresistant MRSA strains tended to have higher MIC values compared to 
nonmultiresistant MRSA or epidemic MRSA 15 phenotypes by E-test (Fisher’s exact P<0.001) 
and VITEK® 2 (Fisher’s exact P<0.001).
Conclusion: Overall diagnostic accuracy and correlations between MIC methods used in 
routine diagnostic laboratories and the gold standard BMD showed limited overall agreement. 
This study helps optimize guidance on the effective use of vancomycin.
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Background
Vancomycin remains the antibiotic of choice for treating serious infection with 
methicillin-resistant Staphylococcus aureus (MRSA) and other serious Gram-positive 
infections despite its continuous use for over half a century.1,2 However, some have 
called into question “how long vancomycin may remain an effective therapy”.3,4 In 
recent years, there have been a number of new agents licensed by the US Food and Drug 
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Administration to treat resistant infection with Gram-positive 
bacteria, including MRSA; however, it is essential to reserve 
these agents for when vancomycin is no longer effective.5, 6
Prudent management of the way in which vancomycin is 
used in therapy is by prompt identification of the organism 
and testing of antibiotic susceptibility, which, along with 
optimizing dosing and serum concentration monitoring, may 
help ensure that vancomycin is not abandoned prematurely.7 
There are a number of methods used to determine minimum 
inhibitory concentration (MIC); however, broth microdilution 
(BMD) remains the gold standard.8 The MIC along with van-
comycin exposure measured as area under the concentration 
curve is the key pharmacokinetic–pharmacodynamic index 
used to optimize bacterial killing and clinical outcomes with 
vancomycin therapy.9,10 An area under the concentration 
curve/MIC index target of 400 mg/L × hour is recommended 
for contemporary vancomycin dosing.11 In the mid-2000s, 
the US Clinical Laboratory Standards Institute (CLSI) rede-
fined the vancomycin MIC susceptibility breakpoint for S. 
aureus to ≤2 µg/mL.12 However, since that time, there have 
been a number of individual studies that have demonstrated 
associations between isolates with vancomycin MIC in the 
susceptible range and patient outcomes.13 Varying methods 
for determining MIC have been used in these studies, which 
makes extrapolation of results to routine clinical management 
challenging. Important consideration must be given to the 
method used to determine MIC, and decisions for treatment 
should be based upon the optimal cutoff points for the various 
methods. A meta-analysis of 14 papers with 2,439 patients 
with susceptible MRSA infection clearly defined high vanco-
mycin MIC as ≥1 µg/mL by BMD and ≥1.5 µg/mL by E-test. 
This meta-analysis, which included patients with bloodstream 
and nonbloodstream infection, found a treatment failure 
risk ratio of 1.40 (95% confidence interval =1.15–1.71) 
and overall mortality risk ratio of 1.42 (confidence interval 
=1.08–1.87) for those with high vancomycin MIC.14
Although BMD remains the gold standard for measuring 
vancomycin MIC, this method is time consuming, labor inten-
sive, and requires a high level of skill for consistent results. 
Alternative methodologies to determine vancomycin MIC 
such as the automated VITEK® 2 (BioMérieux Inc, Durham 
NC, USA) and gradient diffusion E-test are frequently used 
in diagnostic laboratories; however, these methods produce 
varying results in comparison to each other and to BMD.15
Inappropriate interpretation and overestimation of the 
MIC may cause unnecessary use of other agents when van-
comycin would still be effective. Assessing the diagnostic 
accuracy of commonly used MIC methods compared against 
BMD would assist in meaningful interpretation of MIC 
values from each method and application of this informa-
tion to treatment. Unnecessary abandonment of vancomycin 
for newer antibiotics in patients with MRSA infection with 
higher yet susceptible MICs (≥1 and ≤2 µg/mL) will poten-
tially promote the emergence of resistance to these agents. 
Furthermore, the strength of the association among the 
vancomycin method, MIC, and MRSA phenotype is unclear.
The aim of this study was to measure the diagnostic 
accuracy of E-test and VITEK® 2 vancomycin MIC determi-
nation for clinical MRSA isolates compared against a BMD 
standard. A secondary aim was to explore the strength of the 
association between MIC and MRSA antibiotic resistance 
phenotype.
Materials and methods
Study design, data collection, and ethical 
approval
MRSA clinical isolates were obtained from hospitalized 
patients aged ≥18 years during the process of usual care 
between April 2012 and December 2013. The study was 
conducted at Flinders Medical Centre, a 550-bed teaching 
hospital in Adelaide, Australia. The pathology database 
ULTRA Laboratory Information System, Release 2.5C (Cir-
dan, Lisburn, Northern Ireland) was used to identify patient 
isolates during the study period. The study was approved 
by the Southern Adelaide Clinical Human Research Ethics 
Committee (approval number 123.12). A waiver of consent 
was granted with the approval as the participants were not 
exposed to any risk of harm. The waiver of consent was con-
sistent with the Australian Government National Statement 
of Ethical Conduct in Human Research 2007.
Susceptibility testing
All MRSA isolates were tested to determine the vancomycin 
MIC. Isolate susceptibility to vancomycin was defined by the 
CLSI breakpoint of MIC ≤2 µg/mL. Automated VITEK® 2 
System Version 05.04 (BioMérieux Inc.) sensitivity testing 
was performed on fresh isolates during routine processing. 
Gradient diffusion E-test (BioMérieux Inc.) was used accord-
ing to the manufacturer’s instructions. Reading of E-test 
was conducted independently by a senior medical scientist, 
with the result confirmed by a medical microbiologist; any 
disagreement was adjudicated by a third reader. BMD was 
performed using thawed frozen isolates. Frozen isolates 
were stored (−20°C for 6–12 months) to enable batched 
processing. Vancomycin hydrochloride (Sigma-Aldrich, St. 
Louis, MO, USA) was sourced to prepare the stock  solution. 




Optimizing detection of MRSA with elevated vancomycin MIC
Table 1 Anatomical region clinical isolate obtained
Specimen site n %
Skin and soft tissue 94 63.5
Respiratory 26 17.6
Blood/CSF 15 10.1




Abbreviation: CSF, cerebrospinal fluid.
Table 2 Distribution of vancomycin minimum inhibitory 
concentrations (MICs) by three methods in 148 clinical isolates
MIC 
method
0.25 0.38 0.5 0.75 1 1.5 2 3 All MIC range 
(µg/mL)
E-test N/A 3 17 21 54 41 11 1 148 0.38–3
VITEK® 2 N/A N/A 74a N/A 72 N/A 2 N/A 148 ≤0.5–2
BMD 18 N/A 111 5 14 N/A N/A N/A 148 0.25–1
Note: aLowest dilution reported by VITEK® 2 is ≤0.5 µg/mL.
Abbreviations: BMD, broth microdilution; N/A, not applicable.
Table 3 Sensitivity and specificity of E-test and VITEK® 2 for 
detection of a minimum inhibitory concentration (MIC) ≥1 µg/mL 
by broth microdilution (BMD)















 Susceptibility was tested at vancomycin concentrations 
0.25–8.0 µg/mL in twofold dilutions according to the CLSI 
methodology.16
Validation of MIC results obtained using BMD method 
was performed concurrently using S. aureus ATCC 29213 
and Escherichia coli ATCC 25922 as controls for every set 
of tests. MICs were determined after a period of 24 hours 
of incubation at 35°C in oxygen. Reading of BMD was 
performed independently by a senior medical scientist, a 
medical microbiologist, and a specialist pharmacist. Where 
a difference in reading the MIC occurred, a consensus of two 
readers was required.
MRSA resistance phenotype
Phenotyping was determined from antibiogram testing using 
VITEK® 2 AST-612 (BioMérieux Inc.). Three distinct phe-
notypes were recognized. Nonmultiresistant MRSA isolates 
were defined as those resistant to <3 non-β-lactam antibiotic 
classes, while multiresistant MRSA (mMRSA) isolates were 
defined as those resistant to ≥3 non-β-lactam antibiotic 
classes.17 Epidemic MRSA 15 was separately defined by 
resistance to ciprofloxacin ± erythromycin antibiotic.18
Statistical analysis
Data were stored in Microsoft Excel and were reported using 
descriptive statistics. Spearman’s rho (r) correlation coef-
ficients were used to assess the strength of the association 
between the methods used to determine MIC. Specificity, 
sensitivity, and area under the receiver operating character-
istic curve measured as C-statistic were used to calculate 
diagnostic accuracy for VITEK® 2 and E-test MIC methods 
for detecting strains with MIC ≥1 µg/mL by using BMD as 
the reference MIC value. The C-statistic is a measure of 
discrimination and reports the global test accuracy, ie, for 
all cutoff points combined. The reference MIC methodology 
(BMD) and MIC value were selected as they were shown 
to be independent predictors of poor clinical outcomes.14,19 
Fisher’s exact test was used to assess whether MRSA pheno-
type was associated with MIC concentrations for each of the 
three MIC methods. Stata version 14.0 (StataCorp LP, Col-
lege Station, TX, USA) was used for all statistical analyses.
Results
A total of 148 isolates were obtained from 111 patients 
during the study period. The clinical isolates were sourced 
from multiple anatomical sites, with skin and soft tissue and 
respiratory sites featuring prominently and 10% of isolates 
being from blood or central nervous system (Table 1). All 
MRSA isolates, with the exception of one isolate with E-test 
of 3 µg/mL (1 µg/mL by VITEK® 2 and BMD), were sus-
ceptible to vancomycin (≤2 µg/mL) by all the three methods. 
The distribution of MIC values by methodology is shown in 
Table 2. The percentage of isolates with MIC ≤0.5 µg/mL 
was 90.5%, 50%, and 28% by BMD, VITEK® 2, and E-test, 
respectively. MIC values ≥1 µg/mL were observed in 9.5% 
by BMD, 50% by VITEK® 2, and 72% by E-test.
Correlation of MIC methodologies
Spearman’s rho (r) correlation coefficients between the three 
methods were significant but weak; 0.29 for E-test vs VITEK® 2 





(P=0.003), 0.27 for E-test vs BMD (P=0.001), and 0.31 for 
BMD vs VITEK® 2 (P=0.002).
The C-statistic was weak for both E-test (0.5428) and 
VITEK® 2 (0.5815) (Table 3). Sensitivity and specificity for 
detection of an MIC ≥1 µg/mL by BMD were calculated 
for each possible cutoff point for the E-test and VITEK® 2 
methods (Table 3). The optimum cutoff point for the E-test 
was ≥1.0 µg/mL, with a sensitivity of 0.85 and specificity 
of 0.29, while the optimum cutoff point for VITEK® 2 was 
also ≥1.0 µg/mL, with corresponding values of 0.62 and 
0.51, respectively.
Breakdown by phenotype
There was no significant association between MRSA phe-
notype and the BMD MICs (P=0.15), although it appeared 
that there were relatively fewer mMRSA phenotypes than 
expected at BMD =0.25 µg/mL (2.3%), and relatively more 
mMRSA than expected at BMD =0.75 µg/mL (6.8%) based 
on observed percentages for both epidemic MRSA 15 and 
nonmultiresistant MRSA (Table 4). There was a significant 
association between MRSA phenotype and the VITEK® 2 
MIC categories (P<0.001), with a lower than expected percent 
of mMRSA at VITEK® 2 =0.5 µg/mL (27.3%) and a higher 
than expected percent of mMRSA at VITEK® 2 =1.0 µg/mL 
(70.5%) based on the observed percentages for the other two 
MRSA phenotypes. There was also a significant association 
between phenotype and the E-test MICs (P<0.001), with a 
lower than expected percent of mMRSA at E-test =0.5 µg/
mL MICs and 0.75 µg/mL MICs (0%–7%) and a higher than 
expected percent of mMRSA at E-test =1.5 µg/mL and E-test 
=2 µg/mL (39% and 14%) based on the observed percentages 
for the other two MRSA phenotypes.
Discussion
In this study of MRSA isolates that were susceptible to van-
comycin, we found only a weak level of agreement between 
the accepted gold standard BMD and two commonly used 
methods to determine vancomycin MIC (VITEK® 2 and 
E-test). This weak agreement is consistent with the findings 
of other authors.20 Although some authors have reported that 
E-test does not produce higher MIC than other methods,21 
we found higher E-test MIC values than either BMD or 
VITEK® 2, which concurs with the results of other studies.22,23
Patient outcomes are worse for MRSA infection with 
susceptible yet higher vancomycin MICs. Van Hal et al24 in 
a systematic review of 22 papers on the significance of van-
comycin MIC reported that MIC ≥1.5 µg/mL was associated 
with worse clinical outcomes than those with <1.5 µg/mL; 
however, this MIC range was not ascribed to any one MIC 
method. In this study, we used valid statistical approaches to 
compare susceptible MIC values that are obtained in routine 
care from several commonly used methods.
As BMD is acknowledged as the gold standard method 
for MIC testing, and a BMD MIC ≥1 µg/mL has been asso-
ciated with poor clinical outcomes,14,19 we compared the 
diagnostic accuracy of VITEK® 2 and E-test using BMD 
≥1 µg/mL as the defined cutoff point for indicating reduced 
susceptibility. The value of sensitivity and specificity was 
assessed at the various E-test and VITEK® 2 MIC catego-
ries. For the MRSA strains used in this study, the optimum 
E-test and VITEK® 2 cutoff points for detection of reduced 
susceptibility were achieved at ≥1 µg/mL (E-test: sensitivity 
0.85, specificity 0.29; VITEK® 2: sensitivity 0.62, specificity 
0.51). These cutoff points need confirmation in a larger and 
more diverse dataset but provide novel and practical guid-
ance toward assessing MIC results obtained from differing 
methodologies. These findings should prove useful to both 
diagnosticians and clinicians in evaluating test results for 
commonly employed MIC methodologies.
In our study, we observed significant variations in van-
comycin MIC by phenotype using E-test and VITEK® 2, but 
not with BMD. Specifically, mMRSA strains had higher MIC 
Table 4 Relationship between vancomycin minimum inhibitory 
concentration (MIC) by methodology and methicillin-resistant 
Staphylococcus aureus (MRSA) phenotype
MIC (µg/mL) EMRSA-15 mMRSA nmMRSA Total
Broth microdilution method, n (%)
0.25 5 (15.2) 1 (2.3) 12 (17.4) 18 (12.3)
0.5 25 (75.8) 36 (81.8) 50 (72.5) 111 (76.0)
0.75 0 (0.0) 3 (6.8) 2 (2.9) 5 (3.4)
1.0 3 (9.1) 4 (9.1) 5 (7.3) 12 (8.2)
Total 33 (100) 44 (100) 69 (100) 146 (100)
VITEK® 2 method, n (%)
0.5 28 (84.9) 12 (27.3) 33 (47.8) 73 (50)
1.0 5 (15.2) 31 (70.5) 35 (50.7) 71 (48.6)
2.0 0.00 1 (2.3) 1 (1.5) 2 (1.4)
Total 33 (100) 44 (100) 69 (100) 146 (100)
E-test method, n (%)
0.38 0 (0.0) 0 (0.0) 3 (4.4) 3 (2.1)
0.5 5 (15.2) 0 (0.0) 12 (17.4) 17 (11.6)
0.75 8 (24.2) 3 (6.8) 10 (14.5) 21 (14.4)
1.0 16 (48.5) 17 (38.6) 20 (29.0) 53 (36.3)
1.5 3 (9.09) 17 (38.6) 21 (30.4) 41 (28.1)
2.0 1 (3.03) 6 (13.6) 3 (4.4) 10 (6.9)
3.0 0 (0.0) 1 (2.3) 0 (0.0) 1 (0.7)
Total 33 (100) 44 (100) 69 (100) 146 (100)
Note: n=146 (two isolates were unable to be sourced when phenotyping 
performed).
Abbreviations: EMRSA-15, epidemic MRSA; mMRSA, multiresistant MRSA; 
nmMRSA, nonmultiresistant MRSA.
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values than expected. Since mMRSA strains are more likely 
to be  hospital associated, these strains are likely to spread 
in an environment of higher vancomycin usage than the 
other “community-acquired” strains. It is unclear why these 
differences were not detected by BMD, but the clustering 
of BMD MICs at 0.5 µg/mL may have limited the ability to 
detect strain differences.
Guidance on treatment of MRSA infection is based on 
clinical response to vancomycin rather than MIC.25 However, 
if vancomycin MIC is a determinant of antibiotic selection, 
our findings provide useful guidance to better understand-
ing of MIC results obtained through reference and routine 
laboratory methods.
The main limitations of our study were that the clinical 
isolates were obtained from a single geographical region (hos-
pital catchment) and that there were also a relatively small 
number of isolates which were all in the susceptible range.
Conclusion
The level of agreement between MIC determination by BMD, 
E-test, and VITEK® 2 was relatively weak. The estimated 
sensitivity and specificity of the methods provide guidance 
on the best MIC cutoff points to use to interpret the results 
of each method. This permits more objective evaluation of 
test results obtained from routine methods and selection of 
vancomycin when appropriate.
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